Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

Hansson, Oskar LU orcid ; Edelmayer, Rebecca M. ; Boxer, Adam L. ; Carrillo, Maria C. ; Mielke, Michelle M. ; Rabinovici, Gil D. ; Salloway, Stephen ; Sperling, Reisa ; Zetterberg, Henrik LU and Teunissen, Charlotte E. (2022) In Alzheimer's and Dementia 18(12). p.2669-2686
Abstract

Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre-)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease-modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary... (More)

Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre-)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease-modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary endpoints in pivotal trials. Further, we recommend to cautiously start using BBMs in specialized memory clinics as part of the diagnostic work-up of patients with cognitive symptoms and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand-alone diagnostic AD markers, or before considering use in primary care.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, appropriate use recommendations, blood-based biomarkers, diagnosis, prognosis
in
Alzheimer's and Dementia
volume
18
issue
12
pages
2669 - 2686
publisher
Wiley
external identifiers
  • pmid:35908251
  • scopus:85135160575
ISSN
1552-5260
DOI
10.1002/alz.12756
language
English
LU publication?
yes
id
17ea2e62-a813-4d7c-a613-d3fe69d0cecf
date added to LUP
2022-10-11 11:30:44
date last changed
2024-11-16 08:04:27
@article{17ea2e62-a813-4d7c-a613-d3fe69d0cecf,
  abstract     = {{<p>Blood-based markers (BBMs) have recently shown promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD), as well as to improve the design of interventional trials. Here we discuss in detail further research needed to be performed before widespread use of BBMs. We already now recommend use of BBMs as (pre-)screeners to identify individuals likely to have AD pathological changes for inclusion in trials evaluating disease-modifying therapies, provided the AD status is confirmed with positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. We also encourage studying longitudinal BBM changes in ongoing as well as future interventional trials. However, BBMs should not yet be used as primary endpoints in pivotal trials. Further, we recommend to cautiously start using BBMs in specialized memory clinics as part of the diagnostic work-up of patients with cognitive symptoms and the results should be confirmed whenever possible with CSF or PET. Additional data are needed before use of BBMs as stand-alone diagnostic AD markers, or before considering use in primary care.</p>}},
  author       = {{Hansson, Oskar and Edelmayer, Rebecca M. and Boxer, Adam L. and Carrillo, Maria C. and Mielke, Michelle M. and Rabinovici, Gil D. and Salloway, Stephen and Sperling, Reisa and Zetterberg, Henrik and Teunissen, Charlotte E.}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; appropriate use recommendations; blood-based biomarkers; diagnosis; prognosis}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{2669--2686}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease}},
  url          = {{http://dx.doi.org/10.1002/alz.12756}},
  doi          = {{10.1002/alz.12756}},
  volume       = {{18}},
  year         = {{2022}},
}